Loading...

Nexeon MedSystems

OTCPK:NXNN
Snowflake Description

Fair value with mediocre balance sheet.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
NXNN
OTCPK
$3M
Market Cap
  1. Home
  2. US
  3. Healthcare
Company description

Nexeon MedSystems Inc., a medical device company, develops, manufactures, and commercializes neurostimulation technology for the treatment of various neurological disorders through electrical stimulation of neural tissues. The last earnings update was 241 days ago. More info.


Add to Portfolio Compare Print
  • Nexeon MedSystems has significant price volatility in the past 3 months.
NXNN Share Price and Events
7 Day Returns
-54.6%
OTCPK:NXNN
-0.9%
US Medical Equipment
0.6%
US Market
1 Year Returns
-89.5%
OTCPK:NXNN
13.5%
US Medical Equipment
4.1%
US Market
NXNN Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
Nexeon MedSystems (NXNN) -54.6% -47.7% -47.8% -89.5% - -
US Medical Equipment -0.9% 2.4% 12.5% 13.5% 60.9% 101%
US Market 0.6% 3.8% 2.8% 4.1% 37.3% 42.5%
1 Year Return vs Industry and Market
  • NXNN underperformed the Medical Equipment industry which returned 13.5% over the past year.
  • NXNN underperformed the Market in United States of America which returned 4.1% over the past year.
Price Volatility
Industry
5yr Volatility vs Market

Value

 Is Nexeon MedSystems undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
Here we compare the current share price of Nexeon MedSystems to its discounted cash flow analysis.value.

The discounted cash flow value is simply looking at what the company is worth today, based on estimates of how much money it is expected to make in the future.
Raw Data

Below are the data sources, inputs and calculation used to determine the intrinsic value for Nexeon MedSystems.

OTCPK:NXNN Discounted Cash Flow Data Sources
Data Point Source Value
Valuation Model 2 Stage Free Cash Flow to Equity
Levered Free Cash Flow Extrapolated from most recent financials. See below
Discount Rate (Cost of Equity) See below 11.6%
Perpetual Growth Rate 10-Year US Government Bond Rate 2.7%

An important part of a discounted cash flow is the discount rate, below we explain how it has been calculated.

Calculation of Discount Rate/ Cost of Equity for OTCPK:NXNN
Data Point Calculation/ Source Result
Risk-Free Rate 10-Year US Govt Bond Rate 2.7%
Equity Risk Premium S&P Global 6%
Medical Equipment Unlevered Beta Simply Wall St/ S&P Global 0.87
Re-levered Beta = Unlevered beta (1 + (1- tax rate) (Debt/Equity))
= 0.869 (1 + (1- 21%) (125.8%))
1.49
Levered Beta Levered Beta limited to 0.8 to 2.0
(practical range for a stable firm)
1.49
Discount Rate/ Cost of Equity = Cost of Equity = Risk Free Rate + (Levered Beta * Equity Risk Premium)
= 2.73% + (1.49 * 5.96%)
11.61%

Discounted Cash Flow Calculation for OTCPK:NXNN using 2 Stage Free Cash Flow to Equity Model

The calculations below outline how an intrinsic value for Nexeon MedSystems is arrived at by discounting future cash flows to their present value using the 2 stage method. We try to start with analysts estimates of free cash flow, however if these are not available we use the most recent financial results. In the 1st stage we continue to grow the free cash flow over a 10 year period, with the growth rate trending towards the perpetual growth rate used in the 2nd stage. The 2nd stage assumes the company grows at a stable rate into perpetuity.

OTCPK:NXNN DCF 1st Stage: Next 10 year cash flow forecast
Levered FCF (USD, Millions) Source Present Value
Discounted (@ 11.61%)
2020 0.67 Est @ 6.31% 0.60
2021 0.71 Est @ 5.24% 0.57
2022 0.74 Est @ 4.48% 0.53
2023 0.77 Est @ 3.96% 0.50
2024 0.80 Est @ 3.59% 0.46
2025 0.82 Est @ 3.33% 0.43
2026 0.85 Est @ 3.15% 0.39
2027 0.87 Est @ 3.02% 0.36
2028 0.90 Est @ 2.94% 0.33
2029 0.93 Est @ 2.87% 0.31
Present value of next 10 years cash flows $4.48
OTCPK:NXNN DCF 2nd Stage: Terminal Value
Calculation Result
Terminal Value = FCF2029 × (1 + g) ÷ (Discount Rate – g)
= $0.93 × (1 + 2.73%) ÷ (11.61% – 2.73%)
$10.71
Present Value of Terminal Value = Terminal Value ÷ (1 + r)10
= $10.71 ÷ (1 + 11.61%)10
$3.57
OTCPK:NXNN Total Equity Value
Calculation Result
Total Equity Value = Present value of next 10 years cash flows + Terminal Value
= $4.48 + $3.57
$8.05
Equity Value per Share
(USD)
= Total value / Shares Outstanding
= $8.05 / 2.03
$3.97
OTCPK:NXNN Discount to Share Price
Calculation Result
Value per share (USD) From above. $3.97
Current discount Discount to share price of $1.57
= -1 x ($1.57 - $3.97) / $3.97
60.5%

Learn more about our DCF calculations in Simply Wall St’s analysis model .

Current Discount
Amount off the current price Nexeon MedSystems is available for.
Intrinsic value
>50%
Share price is $1.57 vs Future cash flow value of $3.97
Current Discount Checks
For Nexeon MedSystems to be considered undervalued it must be available for at least 20% below the current price. Less than 40% is even better.
  • Nexeon MedSystems's share price is below the future cash flow value, and at a moderate discount (> 20%).
  • Nexeon MedSystems's share price is below the future cash flow value, and at a substantial discount (> 40%).
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for Nexeon MedSystems's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are Nexeon MedSystems's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
OTCPK:NXNN PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2018-09-30) in USD $-0.84
OTCPK:NXNN Share Price ** OTCPK (2019-07-16) in USD $1.57
United States of America Medical Equipment Industry PE Ratio Median Figure of 64 Publicly-Listed Medical Equipment Companies 41.01x
United States of America Market PE Ratio Median Figure of 3,082 Publicly-Listed Companies 17.98x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of Nexeon MedSystems.

OTCPK:NXNN PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= OTCPK:NXNN Share Price ÷ EPS (both in USD)

= 1.57 ÷ -0.84

-1.86x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Nexeon MedSystems is loss making, we can't compare its value to the US Medical Equipment industry average.
  • Nexeon MedSystems is loss making, we can't compare the value of its earnings to the United States of America market.
Price based on expected Growth
Does Nexeon MedSystems's expected growth come at a high price?
Raw Data
OTCPK:NXNN PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section -1.86x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 0 Analysts
Not available
United States of America Medical Equipment Industry PEG Ratio Median Figure of 55 Publicly-Listed Medical Equipment Companies 2.3x
United States of America Market PEG Ratio Median Figure of 2,122 Publicly-Listed Companies 1.59x

*Line of best fit is calculated by linear regression .

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to calculate PEG ratio for Nexeon MedSystems, we can't assess if its growth is good value.
Price based on value of assets
What value do investors place on Nexeon MedSystems's assets?
Raw Data
OTCPK:NXNN PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2018-09-30) in USD $4.65
OTCPK:NXNN Share Price * OTCPK (2019-07-16) in USD $1.57
United States of America Medical Equipment Industry PB Ratio Median Figure of 183 Publicly-Listed Medical Equipment Companies 4.32x
United States of America Market PB Ratio Median Figure of 5,241 Publicly-Listed Companies 1.81x
OTCPK:NXNN PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= OTCPK:NXNN Share Price ÷ Book Value per Share (both in USD)

= 1.57 ÷ 4.65

0.34x

* Primary Listing of Nexeon MedSystems.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Nexeon MedSystems is good value based on assets compared to the US Medical Equipment industry average.
X
Value checks
We assess Nexeon MedSystems's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Medical Equipment industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Medical Equipment industry average (and greater than 0)? (1 check)
  5. Nexeon MedSystems has a total score of 3/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

Future Performance

 How is Nexeon MedSystems expected to perform in the next 1 to 3 years based on estimates from 0 analysts?

In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Nexeon MedSystems has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by Simply Wall St do have past financial data. You can see them here.

Show me the analysis anyway

The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
21.9%
Expected Medical Equipment industry annual growth in earnings.
Earnings growth vs Low Risk Savings
Is Nexeon MedSystems expected to grow at an attractive rate?
  • Unable to compare Nexeon MedSystems's earnings growth to the low risk savings rate as no estimate data is available.
Growth vs Market Checks
  • Unable to compare Nexeon MedSystems's earnings growth to the United States of America market average as no estimate data is available.
  • Unable to compare Nexeon MedSystems's revenue growth to the United States of America market average as no estimate data is available.
Annual Growth Rates Comparison
Raw Data
OTCPK:NXNN Future Growth Rates Data Sources
Data Point Source Value (per year)
United States of America Medical Equipment Industry Earnings Growth Rate Market Cap Weighted Average 21.9%
United States of America Medical Equipment Industry Revenue Growth Rate Market Cap Weighted Average 7.8%
United States of America Market Earnings Growth Rate Market Cap Weighted Average 14.1%
United States of America Market Revenue Growth Rate Market Cap Weighted Average 7.4%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
OTCPK:NXNN Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (9 months ago) See Below
Future Estimates Average of up to 0 Analyst Estimates (S&P Global) See Below
All numbers in USD Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
OTCPK:NXNN Future Estimates Data
Date (Data in USD Millions) Revenue Cash Flow Net Income * Avg. No. Analysts
OTCPK:NXNN Past Financials Data
Date (Data in USD Millions) Revenue Cash Flow Net Income *
2018-09-30 10 1 -2
2018-06-30 9 -1 -1
2018-03-31 6 -3 -1
2017-12-31 3 -3 -2
2017-09-30 1 -4 -5
2017-06-30 0 -2 -5
2017-03-31 2 -1 -2
2016-12-31 1 0 -1
2015-12-31 0 0

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • Unable to determine if Nexeon MedSystems is high growth as no earnings estimate data is available.
  • Unable to determine if Nexeon MedSystems is high growth as no revenue estimate data is available.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
OTCPK:NXNN Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (9 months ago) See Below
Future Estimates Average of up to 0 Analyst Estimates (S&P Global) See Below

All data from Nexeon MedSystems Company Filings, last reported 9 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

OTCPK:NXNN Future Estimates Data
Date (Data in USD Millions) EPS * EPS High Estimate EPS Low Estimate Avg. No. Analysts
OTCPK:NXNN Past Financials Data
Date (Data in USD Millions) EPS *
2018-09-30 -0.84
2018-06-30 -0.35
2018-03-31 -0.77
2017-12-31 -1.23
2017-09-30 -2.83
2017-06-30 -3.19
2017-03-31 -1.63
2016-12-31 -0.59
2015-12-31

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • Unable to establish if Nexeon MedSystems will efficiently use shareholders’ funds in the future without estimates of Return on Equity.

Next steps:

  1. Examine whether Nexeon MedSystems is trading at Nexeon MedSystems'san attractive price based on how much it is expected to earn in the future, and relative to its industry peers and the wider market.
  2. Nexeon MedSystems's future outlook can be gauged by looking at industry trends and market size, and determining how well-positioned the company is compared to its competitors. Take a look at other high-growth Healthcare companies here
  3. While we do not consider unaudited financials to be a reliable enough to include in our analysis, you can access them on the OTC Markets Website. If you are looking for more of a qualitative research into the company, you can access Nexeon MedSystems's filings and announcements here.
  4. Use fundamentals to screen for another stock to analyse from our database of over 75,000 companies worldwide
X
Future performance checks
We assess Nexeon MedSystems's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the United States of America market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the United States of America market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
Nexeon MedSystems has a total score of 0/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

Past Performance

  How has Nexeon MedSystems performed over the past 5 years?

  • Nexeon MedSystems's last earnings update was 241 days ago.
The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare Nexeon MedSystems's growth in the last year to its industry (Medical Equipment).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • Nexeon MedSystems does not make a profit and there is insufficient past data to establish if their 5 year on year earnings growth rate was positive.
  • Unable to compare Nexeon MedSystems's 1-year earnings growth to the 5-year average as it is not currently profitable.
  • Unable to compare Nexeon MedSystems's 1-year growth to the US Medical Equipment industry average as it is not currently profitable.
Earnings and Revenue History
Nexeon MedSystems's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from Nexeon MedSystems Company Filings, last reported 9 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

OTCPK:NXNN Past Revenue, Cash Flow and Net Income Data
Date (Data in USD Millions) Revenue Net Income * G+A Expenses R&D Expenses
2018-09-30 9.82 -1.65 3.74 3.16
2018-06-30 8.88 -0.68 3.85 2.85
2018-03-31 6.16 -1.45 3.12 2.78
2017-12-31 3.30 -2.18 2.83 2.94
2017-09-30 1.15 -4.76 2.09 2.20
2017-06-30 0.30 -4.92 1.66 2.14
2017-03-31 1.50 -2.35 1.32 1.44
2016-12-31 1.49 -0.80 0.69 0.76
2015-12-31 -0.01 0.01

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • It is difficult to establish if Nexeon MedSystems has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) as it is loss-making.
  • It is difficult to establish if Nexeon MedSystems has efficiently used its assets last year compared to the US Medical Equipment industry average (Return on Assets) as it is loss-making.
  • It is difficult to establish if Nexeon MedSystems improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.
X
Past performance checks
We assess Nexeon MedSystems's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Medical Equipment industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
Nexeon MedSystems has a total score of 0/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

Health

 How is Nexeon MedSystems's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up Nexeon MedSystems's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • Nexeon MedSystems's short term (1 year) commitments are greater than its holdings of cash and other short term assets.
  • Nexeon MedSystems's cash and other short term assets cover its long term commitments.
Balance sheet
This treemap shows a more detailed breakdown of Nexeon MedSystems's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • High level of physical assets or inventory.
  • Debt is covered by short term assets, assets are 1.3x debt.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from Nexeon MedSystems Company Filings, last reported 9 months ago.

OTCPK:NXNN Past Debt and Equity Data
Date (Data in USD Millions) Total Equity Total Debt Cash & Short Term Investments
2018-09-30 9.14 3.37 0.13
2018-06-30 10.38 3.39 0.34
2018-03-31 11.17 3.70 0.35
2017-12-31 11.87 3.44 0.88
2017-09-30 9.88 4.21 0.76
2017-06-30 10.00 0.03 0.21
2017-03-31 9.77 0.03 0.61
2016-12-31 11.32 0.20 2.12
2015-12-31 0.00 0.00
  • Nexeon MedSystems's level of debt (43.8%) compared to net worth is high (greater than 40%).
  • Unable to establish if Nexeon MedSystems's debt level has increased without past 5-year debt data.
CASH RUNWAY ANALYSIS

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

  • Whilst loss making Nexeon MedSystems has sufficient cash runway for more than 3 years if it maintains the current positive free cash flow level.
  • Whilst loss making Nexeon MedSystems has sufficient cash runway for more than 3 years, due to free cash flow being positive and growing by 24.1% per year.
X
Financial health checks
We assess Nexeon MedSystems's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. Nexeon MedSystems has a total score of 3/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

Dividends

 What is Nexeon MedSystems's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
0%
Current annual income from Nexeon MedSystems dividends.
If you bought $2,000 of Nexeon MedSystems shares you are expected to receive $0 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • Unable to evaluate Nexeon MedSystems's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
  • Unable to evaluate Nexeon MedSystems's dividend against the top 25% market benchmark as the company has not reported any payouts.
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
OTCPK:NXNN Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 0 Analyst Estimates (S&P Global) See Below
United States of America Medical Equipment Industry Average Dividend Yield Market Cap Weighted Average of 24 Stocks 1.2%
United States of America Market Average Dividend Yield Market Cap Weighted Average of 2017 Stocks 2.4%
United States of America Minimum Threshold Dividend Yield 10th Percentile 0.8%
United States of America Bottom 25% Dividend Yield 25th Percentile 1.4%
United States of America Top 25% Dividend Yield 75th Percentile 3.7%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

OTCPK:NXNN Future Dividends Estimate Data
Date (Data in $) Dividend per Share (annual) Avg. No. Analysts

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to perform a dividend volatility check as Nexeon MedSystems has not reported any payouts.
  • Unable to verify if Nexeon MedSystems's dividend has been increasing as the company has not reported any payouts.
Current Payout to shareholders
What portion of Nexeon MedSystems's earnings are paid to the shareholders as a dividend.
  • Unable to calculate sustainability of dividends as Nexeon MedSystems has not reported any payouts.
Future Payout to shareholders
  • Insufficient estimate data to determine if a dividend will be paid in 3 years and that it will be sustainable.
X
Income/ dividend checks
We assess Nexeon MedSystems's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 0.8%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can Nexeon MedSystems afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. Nexeon MedSystems has a total score of 0/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

Management

 What is the CEO of Nexeon MedSystems's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
CEO
Will Rosellini
COMPENSATION $2
AGE 39
TENURE AS CEO 3.6 years
CEO Bio

Mr. William Rosellini, also known as Will, JD, MBA, serves as Principal at Growth Stack, Inc. He has been the Chief Executive Officer at Nexeon MedSystems, Inc. since December 7, 2015 and serves as its Chairman. He serves as Chief Executive Officer of Perimeter Medical, Inc. Mr. Rosellini founded Nuviant Medical, Inc in 2014 and also served as its Chief Executive Officer. He is a 15-year veteran of the neurotechnology space and has expertise in accelerating the development of emerging technologies with minimal at-risk capital. Mr. Rosellini previously founded and led Lexington Technology Group (later known as DSS Technology Management, Inc.), Sarif Biomedical LLC, and Telemend Medical. He founded Microtransponder in 2006 and served as its Chief Executive Officer and President. He has since been acquiring technology and intellectual property, launching preclinical and clinical programs and raising non-dilutive and at-risk capital to support the launch of Nexeon’s next generation of viable medtech products and associated remote management software platforms. He served as Chairman of Rosellini Scientific, LLC. Mr. Rosellini served as the Chairman of the Board at MicroTransponder, Inc. He has been a Director of Nexeon MedSystems, Inc. since December 7, 2015. He served as an Independent Director at Marathon Patent Group, Inc. from March 8, 2013 to September 28, 2016. Mr. Rosellini is a former minor-league pitcher, holds five master’s degrees in addition to a law degree. Mr. Rosellini holds an MBA from the University of Texas System; MS in Accounting from The University of Texas System; an MS in Bio-informatics from Rutgers, The State University of New Jersey; an MS in Neuroscience from University of Texas; and an MS of Regulatory Science from USC. He also holds a BA in Economics degree from University Of Dallas. He also holds a Juries Doctor degree from Hofstra Law.

CEO Compensation
  • Will's compensation has been consistent with company performance over the past year, both up more than 20%.
  • Insufficient data for Will to establish whether their remuneration is reasonable compared to companies of similar size in United States of America.
Management Team

Will Rosellini

TITLE
Chairman & CEO
COMPENSATION
$2
AGE
39
TENURE
3.6 yrs

Christopher Miller

TITLE
Chief Financial Officer
COMPENSATION
$132K
AGE
49
TENURE
3.5 yrs

Cathal Mc Fadden

TITLE
Vice President of Operations

Austin Duke

TITLE
Chief Science Officer
Board of Directors

Will Rosellini

TITLE
Chairman & CEO
COMPENSATION
$2
AGE
39

Kent George

TITLE
Independent Director
COMPENSATION
$37K
AGE
59
TENURE
2.5 yrs

Michael Neitzel

TITLE
Independent Director
COMPENSATION
$37K
AGE
40
TENURE
2.5 yrs

Mark Wholey

TITLE
Scientific & Clinical Advisor

Steve Ramee

TITLE
Scientific & Clinical Advisor

Michael Jaff

TITLE
Scientific & Clinical Advisor

Juan Parodi

TITLE
Scientific & Clinical Advisor

Takao Ohki

TITLE
Scientific & Clinical Advisor

William Gray

TITLE
Scientific & Clinical Advisor

Peter Gaines

TITLE
Scientific & Clinical Advisor
Who owns this company?
Recent Insider Trading
  • No 3 month individual insider trading information.
Recent Insider Transactions
Announced Type Name Entity Role Start End Shares Max Price ($) Value ($)
X
Management checks
We assess Nexeon MedSystems's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. Nexeon MedSystems has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

News

Simply Wall St News

Company Info

Description

Nexeon MedSystems Inc., a medical device company, develops, manufactures, and commercializes neurostimulation technology for the treatment of various neurological disorders through electrical stimulation of neural tissues. Its neurostimulation technology platform would provide treatment to patients in several neurostimulator markets, including deep brain stimulation, peripheral electrical nerve stimulation, sacral nerve stimulation, spinal cord stimulation, vagus nerve stimulation, and other neurostimulator markets. The company develops the Viant, a deep brain stimulation system for Parkinson’s disease in the United States, as well as for Parkinson’s disease, Essential Tremor, and Dystonia in Europe. Nexeon MedSystems Inc. was founded in 2015 and is based in Dallas, Texas.

Details
Name: Nexeon MedSystems Inc.
NXNN
Exchange: OTCPK
Founded: 2015
$3,180,744
2,025,952
Website: http://www.nexeonmed.com
Address: Nexeon MedSystems Inc.
1910 Pacific Avenue,
Suite 20000,
Dallas,
Texas, 75201,
United States
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
OTCPK NXNN Common Shares Pink Sheets LLC US USD 03. Aug 2017
Number of employees
Current staff
Staff numbers
62
Nexeon MedSystems employees.
Industry
Health Care Equipment
Healthcare
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2019/07/18 01:07
End of day share price update: 2019/07/16 00:00
Last estimates confirmation: 2018/04/05
Last earnings filing: 2018/11/19
Last earnings reported: 2018/09/30
Last annual earnings reported: 2017/12/31


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.